Ohmeda to distribute clave connector in Europe:
This article was originally published in Clinica
Executive Summary
Ohmeda has been awarded exclusive distribution rights for ICU Medical's clave connector in most of Europe. The product is a needleless device for the intravenous administration of medicines and other fluids. It can also be used to extract blood samples. Ohmeda intends to develop distribution in the UK, France and Benelux before introducing the product into Spain, Germany, Austria and Switzerland. Ohmeda is the healthcare division of UK company BOC. ICU Medical, which is based in San Clemente, California, distributes its product in the US, together with other companies.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.